About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 465179, 10 pages
http://dx.doi.org/10.1155/2013/465179
Research Article

Molecular Characterization and Clinical Impact of TMPRSS2-ERG Rearrangement on Prostate Cancer: Comparison between FISH and RT-PCR

1Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, C/Professor Beltrán Báguena 8, 46009 Valencia, Spain
2Department of Pathology, Fundación Instituto Valenciano de Oncología, C/Professor Beltrán Báguena 8, 46009 Valencia, Spain
3Department of Urology, Fundación Instituto Valenciano de Oncología, C/Professor Beltrán Báguena 8, 46009 Valencia, Spain
4Laboratori de Citogenètica Molecular, Servei de Patologia, GRETNHE, Programa de Recerca en Càncer, IMIM, Institut de Recerca del Hospital del Mar, Parc de Salut Mar, 08003 Barcelona, Spain
5Department of Pathology, Universitat de Valencia Estudi General, 46010 Valencia, Spain

Received 26 December 2012; Accepted 30 April 2013

Academic Editor: Sachidanand Pandey

Copyright © 2013 A. Fernández-Serra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. H. Hayes, D. A. Ollendorf, S. D. Pearson et al., “Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis,” Journal of the American Medical Association, vol. 304, no. 21, pp. 2373–2380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. A. H. Thomson, S. Kulkarni, and A. Bahl, “Primary cryotherapy with salvage external beam radiotherapy for locally recurrent prostate cancer,” Clinical Oncology, vol. 20, no. 5, p. 385, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Rabbani, N. Stroumbakis, B. R. Kava, M. S. Cookson, and W. R. Fair, “Incidence and clinical significance of false-negative sextant prostate biopsies,” The Journal of Urology, vol. 159, no. 4, pp. 1247–1250, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. S. A. Tomlins, D. R. Rhodes, S. Perner et al., “Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer,” Science, vol. 310, no. 5748, pp. 644–648, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. S. A. Tomlins, R. Mehra, D. R. Rhodes et al., “TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer,” Cancer Research, vol. 66, no. 7, pp. 3396–3400, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. S. A. Narod, A. Seth, and R. Nam, “Fusion in the ETS gene family and prostate cancer,” British Journal of Cancer, vol. 99, no. 6, pp. 847–851, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. S. A. Tomlins, B. Laxman, S. Varambally et al., “Role of the TMPRSS2-ERG gene fusion in prostate cancer,” Neoplasia, vol. 10, no. 2, pp. 177–188, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. A. Tomlins, A. Bjartell, A. M. Chinnaiyan et al., “ETS gene fusions in prostate cancer: from discovery to daily clinical practice,” European Urology, vol. 56, no. 2, pp. 275–286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Fernández-Serra, J. Rubio-Briones, Z. García-Casado, E. Solsona, and J. A. López-Guerrero, “Prostate cancer: the revolution of the fusion genes,” Actas Urologicas Espanolas, vol. 35, no. 7, pp. 420–428, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. Q. P. Sun, L. Y. Li, Z. Chen et al., “Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study,” Journal of Molecular Diagnostics, vol. 12, no. 5, pp. 718–724, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Yoshimoto, J. C. Cutz, P. A. S. Nuin et al., “Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias,” Cancer Genetics and Cytogenetics, vol. 169, no. 2, pp. 128–137, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Attard, J. Clark, L. Ambroisine et al., “Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer,” Oncogene, vol. 27, no. 3, pp. 253–263, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Attard, J. Clark, L. Ambroisine et al., “Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer,” British Journal of Cancer, vol. 99, no. 2, pp. 314–320, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Perner, F. Demichelis, R. Beroukhim et al., “TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer,” Cancer Research, vol. 66, no. 17, pp. 8337–8341, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Lu, B. Maqsodi, W. Yang et al., “Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA,” Urology, vol. 74, no. 5, pp. 1156–1161, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Yoshimoto, A. M. Joshua, S. Chilton-MacNeill et al., “Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement,” Neoplasia, vol. 8, no. 6, pp. 465–469, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Demichelis, K. Fall, S. Perner et al., “TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort,” Oncogene, vol. 26, no. 31, pp. 4596–4599, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Rubio-Briones, A. Fernández-Serra, A. Calatrava et al., “Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy,” The Journal of Urology, vol. 183, no. 5, pp. 2054–2061, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Djavan, M. Remzi, C. C. Schulman, M. Marberger, and A. R. Zlotta, “Repeat prostate biopsy: who, how and when? A review,” European Urology, vol. 42, no. 2, pp. 93–103, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. J. M. Mosquera, S. Perner, E. M. Genega et al., “Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications,” Clinical Cancer Research, vol. 14, no. 11, pp. 3380–3385, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. J. J. Tu, S. Rohan, J. Kao, N. Kitabayashi, S. Mathew, and Y. T. Chen, “Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues,” Modern Pathology, vol. 20, no. 9, pp. 921–928, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Yoshimoto, A. M. Joshua, I. W. Cunha et al., “Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome,” Modern Pathology, vol. 21, no. 12, pp. 1451–1460, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Pflueger, D. S. Rickman, A. Sboner et al., “N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer,” Neoplasia, vol. 11, no. 8, pp. 804–811, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Han, R. Mehra, S. M. Dhanasekaran et al., “A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer,” Cancer Research, vol. 68, no. 18, pp. 7629–7637, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. M. J. Soller, M. Isaksson, P. Elfving, W. Soller, R. Lundgren, and I. Panagopoulos, “Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer,” Genes Chromosomes and Cancer, vol. 45, no. 7, pp. 717–719, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. S. A. Tomlins, R. Mehra, D. R. Rhodes et al., “Integrative molecular concept modeling of prostate cancer progression,” Nature Genetics, vol. 39, no. 1, pp. 41–51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Machado, R. Noguera, A. Pellin et al., “Molecular diagnosis of ewing sarcoma family of tumors: a comparative analysis of 560 cases with fish and rt-pcr,” Diagnostic Molecular Pathology, vol. 18, no. 4, pp. 189–199, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Salgado, B. Llombart, R. M. Pujol et al., “Molecular diagnosis of dermatofibrosarcoma protuberans: a comparison between reverse transcriptase-polymerase chain reaction and fluorescence in situ hybridization methodologies,” Genes Chromosomes and Cancer, vol. 50, no. 7, pp. 510–517, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. K. G. Hermans, J. L. Boormans, D. Gasi et al., “Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer,” Clinical Cancer Research, vol. 15, no. 20, pp. 6398–6403, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Wang, Y. Cai, C. Ren, and M. Ittmann, “Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer,” Cancer Research, vol. 66, no. 17, pp. 8347–8351, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. R. S. Bridge, V. Rajaram, L. P. Dehner, J. D. Pfeifer, and A. Perry, “Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue: a comparison of two FISH strategies and RT-PCR in malignant round cell tumors,” Modern Pathology, vol. 19, no. 1, pp. 1–8, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. T. B. Lewis, C. M. Coffin, and P. S. Bernard, “Differentiating Ewing's sarcoma from other round blue cell tumors using a RT-PCR translocation panel on formalin-fixed paraffin-embedded tissues,” Modern Pathology, vol. 20, no. 3, pp. 397–404, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. M. L. Wallander, K. B. Geiersbach, S. R. Tripp, and L. J. Layfield, “Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing,” Archives of Pathology & Laboratory Medicine, vol. 136, no. 7, pp. 796–803, 2012.
  34. L. Dvorak, M. Dolan, J. Fink, L. Varghese, J. Henriksen, and H. E. Gulbahce, “Correlation between HER2 determined by fluorescence in situ hybridization and reverse transcription-polymerase chain reaction of the oncotype DX test,” Applied Immunohistochemistry & Molecular Morphology, vol. 21, no. 3, pp. 196–199, 2013.
  35. F. L. Baehner, N. Achacoso, T. Maddala et al., “Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories,” Journal of Clinical Oncology, vol. 28, no. 28, pp. 4300–4306, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. A. L. Folpe, J. R. Goldblum, B. P. Rubin et al., “Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases,” American Journal of Surgical Pathology, vol. 29, no. 8, pp. 1025–1033, 2005. View at Scopus
  37. S. Kumar, S. Pack, D. Kumar et al., “Detection of EWS-FLI-1 fusion in Ewing's sarcoma/peripheral primitive neuroectodermal tumor by fluorescence in situ hybridization using formalin-fixed paraffin-embedded tissue,” Human Pathology, vol. 30, no. 3, pp. 324–330, 1999. View at Scopus
  38. M. K. Fritsch, J. A. Bridge, A. E. Schuster, E. J. Perlman, and P. Argani, “Performance characteristics of a reverse transcriptase-polymerase chain reaction assay for the detection of tumor-specific fusion transcripts from archival tissue,” Pediatric and Developmental Pathology, vol. 6, no. 1, pp. 43–53, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. O. R. Saramäki, A. E. Harjula, P. M. Martikainen, R. L. Vessella, T. L. J. Tammela, and T. Visakorpi, “TMPRSS2.ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis,” Clinical Cancer Research, vol. 14, no. 11, pp. 3395–3400, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Petrovics, A. Liu, S. Shaheduzzaman et al., “Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome,” Oncogene, vol. 24, no. 23, pp. 3847–3852, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. A. B. Rajput, M. A. Miller, A. de Luca et al., “Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers,” Journal of Clinical Pathology, vol. 60, no. 11, pp. 1238–1243, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Gopalan, M. A. Leversha, J. M. Satagopan et al., “TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy,” Cancer Research, vol. 69, no. 4, pp. 1400–1406, 2009. View at Publisher · View at Google Scholar
  43. S. A. Tomlins, S. M. Aubin, J. Siddiqui et al., “Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA,” Science Translational Medicine, vol. 3, no. 94, Article ID 94ra72, 2011. View at Publisher · View at Google Scholar